ASD
Insomnia in Children with ASD: Challenges of Off-label Pharmacotherapy


Autism Spectrum Disorder - Continue Your Journey
We work with leading experts in the field to design meeting programmes that explore key issues in ASD.
50% to 75% of children with neurodevelopmental or phychiatric comorbidities experience paediatric insomnia
Insomnia in Children with ASD: The Aetiological Role of Melatonin
Slenyto® (paediatric prolonged-release melatonin) for:
- treatment of insomnia in children and adolescents aged 2-18 years with Autism Spectrum Disorder (ASD), and/or neurogenetic disorders with aberrant diurnal melatonin secretion and/or nocturnal awakenings, where sleep hygiene measures have been insufficient
- treatment of insomnia in children and adolescents aged 6-17 years with attention-deficit hyperactivity disorder (ADHD) where sleep hygiene measures have been insufficient
- significant improvements, over baseline, in total sleep time, sleep initiation (latency) and maintenance, child behaviours (externalising), caregivers’ quality of life and resolution of caregiver sleep disturbance
References
- Gringras, P. et al. Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder. J Am Acad Child Adolesc Psychiatry. 2017;56(11):948-957
- Maras, A. et al. Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder. Jnl Child and Adolesc Psychpharmacol. 2018; doi 10.1089:1-12
- Chua, HM. et al. Dissolution of Intact, Divided and Crushed Circadin Tablets: Prolonged vs. Immediate Release of Melatonin. Jnl Pharmaceutics. 2016;8(2):1-11
- Gringras P, et al. Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo-controlled trial. BMJ. 2012;345:e6664







